Bruker

Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.

Revenues in the third quarter grew to $466.6 million from $335.6 million in Q3 2017, beating the consensus Wall Street estimate of $451.7 million.

The group's meeting this week evidenced the ongoing shift towards analyzing proteins in the context of specific isoforms, complexes, and cells.

Bruker plans to acquire an 80 percent stake in Hain, which has capabilities in tuberculosis and mycobacteria testing as well as virology and human genetics.

The company reported revenues of $443.7 million and organic growth of 3 percent, driven in large part by strength in its scientific instruments business.

JPK provides microscopy instrumentation for biomolecular and cellular imaging, as well as force measurements on single molecules, cells, and tissues.

Major releases were relatively sparse at ASMS as many vendors focused instead on the development of applications and workflows for their existing platforms.

The company reported total revenues of $431.7 million for the three months ended March 31, beating analysts' consensus estimate of $417.4 million.

Pages

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.